REC-2282

Drug identity checked against registry records

Also recorded as AR-42; NSC-D736012; OSU-HDAC42

A drug appearing in a clinical trial does not mean it is FDA-approved. Check the original regulatory source for any approval claim.

Included trials

TrialSponsorPhaseStatusPrimary completion
Efficacy and Safety of REC-2282 in Patients With Progressive Neurofibromatosis Type 2 (NF2) Mutated MeningiomasNCT05130866RXRXPhase 2, Phase 3Terminated2025-08-18Actual

Regulatory dates and decisions

No regulatory events match this view.This does not mean no FDA events have occurred.